We first acquired the stem cells from the red receptacles of a local hospital’s labor and delivery ward, delivered to our lab at the University of Southern California. I would reach into the large medical waste containers and pull out the tree-like branches of the placenta, discarded after a baby had been born. Squeezing the umbilical cord that had so recently been attached to new life, the blood, laden with stem cells, would come dripping out.
But sometimes a different package would arrive at our lab. Despite my distaste for wringing placentas, I felt more squeamish about what lay inside the unassuming white box. Packed in the ice was a crescent-shaped sliver of dark red tissue: a human liver. Just like the placentas that were discarded after birth, this tissue was originally destined for medical waste following an abortion.
Stem cell science is a big deal in California, thanks to the Institute for Regenerative Medicine, a state agency that has allocated almost $2 billion in research grants since 2004 (federal funding is still highly restricted). To meet the demand for cells, researchers turned to a procedure protected by federal law: abortions. The discarded tissue from terminated pregnancies, performed up to 24 weeks in California, is a rich source of stem cells.
To meet the need for these precursor cells, biotech companies form an essential middleman
between tissuedonated from abortion clinics and the research labs that need it. They ensure that informed consent is obtained, harvest the organs, in some cases isolate and purify the cells and then ship them out to laboratories. There are profits to be made by such middlemen in what critics call the abortion industry. A fetus runs upward of $850, not including testing, cleaning or shipping charges, while a vial packed with pure stem cells can fetch more than $20,000.
The use of fetal tissue in research is not new. Fetal cells extracted from the lungs of two aborted fetuses from Europe in the 1960s are still being propagated in cell culture. They’re so successful that today we still use them to produce vaccines for hepatitis A, rubella, chickenpox and shingles. From two terminated pregnancies, countless lives have been spared.
It isn’t just vaccines. Scientists at the University of California, San Diego, have injected neural stem cells into two patients to treat their spinal cord injuries. And progress is being made in the use of stem-cell therapies against cancer, blindness, Alzheimer’s, heart disease, HIV and diabetes.
As impressive as this is, for critics the lives saved cannot make up for those that have been lost. And as important as I believe my research was, I sympathize with that sense of loss, even after leaving the lab for Boston.
Still, even with our preparations, justifications and the sheer excitement that accompanied our research, the fetal cells brought sadness.
We wished we didn’t have them, despite the breakthroughs.
Politicians aren’t the only ones looking for answers. Scientists are searching for alternatives to fetal cells. One solution may lie in reprogramming adult cells, creating what researchers call induced pluripotent stem cells. These cells share the ancestral adaptability of embryonic stem cells, yet can also be manipulated to look and act like fetal stem cells.
The choice I made is repeated every day, in labs all over the world. Researchers have no say in whether a fetus is aborted or develops into a human baby; those decisions are made by women and shaped by politicians. Yet their science, performed on discarded tissue, has the ability to save lives. It already has.
The New York Times
Nathalia Holt, a microbiologist, is the author of “Cured: The People Who Defeated HIV.”